ABBV Q3: sales up 10.3% to $17.4B, in line with estimates, EPS slightly higher
FROM THE WIRE · FINANCE.YAHOO.COM
Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street's revenue expectations in Q3 2026, with sales up 10.3% year on year to $17.4 billion. Its non-GAAP profit of $3.82 per share was 1.3% above analysts' consensus estimates. Is now the time to buy ABBV? Find out in our full…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishQuarter in line on revenue and slightly above on EPS, with full-year guidance reiterated.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Revenue of $17.4 billion was in line with estimates.
- 02Adjusted EPS of $3.82 compared with estimates of $3.77.
- 03Full-year adjusted EPS guidance of $13.97 at the midpoint was reiterated.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets